within Pharmacolibrary.Drugs.ATC.G;

model G03CA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Estradiol, in combination with other agents such as progestins, is a medication used primarily for hormone replacement therapy (HRT) in menopausal women to treat symptoms of estrogen deficiency, such as hot flashes and osteoporosis prevention. It can also be used in transgender women and sometimes for contraception. These combinations are approved and in clinical use today, although formulations and combinations may vary by country.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic model in healthy postmenopausal women. Parameters are based on oral administration of estradiol valerate in combination products; values serve as reasonable clinical estimates where direct studies are lacking for this specific ATC subgroup.</p><h4>References</h4><ol><li><p>Battipaglia, C, et al., &amp; Grandi, G (2023). Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 871–879. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2279752&quot;>10.1080/17425255.2023.2279752</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37942662/&quot;>https://pubmed.ncbi.nlm.nih.gov/37942662</a></p></li><li><p>Stanczyk, FZ, et al., &amp; Archer, DF (2024). Comparison of estrogenic components used for hormonal contraception. <i>Contraception</i> 130 110310–None. DOI:<a href=&quot;https://doi.org/10.1016/j.contraception.2023.110310&quot;>10.1016/j.contraception.2023.110310</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37863464/&quot;>https://pubmed.ncbi.nlm.nih.gov/37863464</a></p></li><li><p>Regidor, PA, et al., &amp; Mayr, M (2023). Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. <i>Women&#x27;s health (London, England)</i> 19 17455057221147388–None. DOI:<a href=&quot;https://doi.org/10.1177/17455057221147388&quot;>10.1177/17455057221147388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744531/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744531</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03CA53;
